Basic Information
SERETIDE EVOHALER 25/250 mcg
AEROSOL, SPRAY
Regulatory Information
SIN11531P
May 24, 2001
Prescription Only
Therapeutic
RESPIRATORY (INHALATION)
August 10, 2023
June 3, 2025
XR03AK06
Company Information
Active Ingredients
Strength: 25 mcg
Strength: 250 mcg
Detailed Information
Contraindications
**Contraindications** Seretide is contraindicated in patients with a history of hypersensitivity to any of the ingredients.
Indication Information
**Indications** Pharmaceutical form: Inhalation aerosol. **Asthma** Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting-beta2-agonist and inhaled corticosteroid) is appropriate: - Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting-beta2-agonist or - Patients already adequately controlled on both inhaled corticosteroids and long-acting-beta2-agonist Note: Seretide 25/50 mcg strength is not appropriate in adults with severe asthma.